Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease

Diabetes and Vascular Disease Research

Volumn 7, Issue 4, 2010, Pages 274-288

  Ferreiro, José Luis ^a   Cequier, Ãngel R ^a   Angiolillo, Dominick J ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antithrombotic therapy; coronary artery disease; diabetes mellitus; platelets

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTICOAGULANT AGENT; APIXABAN; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; E 5555; ELINOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; INSULIN; PICOTAMIDE; PLACEBO; PRASUGREL; RAMATROBAN; RIDOGREL; RIVAROXABAN; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; THROMBIN RECEPTOR ANTAGONIST; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; INSULIN TREATMENT; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SECONDARY PREVENTION; STENT THROMBOSIS;

CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 79551691089     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164110383995     Document Type: Review

References (132)

1. Zimmet P., Alberti KG and Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001 ; 414: 782-787. (Pubitemid 34000780)
2. King H., Aubert RE and Herman WH Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 ; 21: 1414-1431. (Pubitemid 28405191)
3. Bartnik M., Rydén L., Ferrari R., et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004 ; 25: 1880-1890. (Pubitemid 39452604)
4. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004 ; 292: 2096-2104. (Pubitemid 39435100)
5. Roe MT, Parsons LS, Pollack CV Jr, et al. Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med 2005 ; 165: 1630-1636. (Pubitemid 41124158)
6. Webster MW and Scott RS What cardiologists need to know about diabetes. Lancet 1997 ; 350 (Suppl 1). S123 - S128.
7. Centers for Disease Control and Prevention. 2007 National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, www.cdc.gov/diabetes/pubs/factsheet07.htm ( 2007, accessed September 2010 ).
8. Davì G. and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007 ; 357: 2482-2494.
9. Creager MA, Lüscher TF, Cosentino F. and Beckman JA Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003 ; 108: 1527-1532. (Pubitemid 37176462)
10. Stratmann B. and Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005 ; 2: 16-23. (Pubitemid 40333200)
11. Ferroni P., Basili S., Falco A. and Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004 ; 2: 1282-1291. (Pubitemid 40186123)
12. Angiolillo DJ, Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005 ; 54: 2430-2435. (Pubitemid 41134272)
13. Ferreiro JL and Angiolillo DJ Diabetes and anti-platelet therapy in acute coronary syndrome. Circulation 2010 (in press).
14. Geisler T., Anders N., Paterok M., et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007 ; 30: 372-374. (Pubitemid 46198349)
15. Angiolillo DJ Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009 ; 32: 531-540.
16. Angiolillo DJ, Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007 ; 49: 1505-1516. (Pubitemid 46517957)
17. Ferreiro JL and Angiolillo DJ Clopidogrel response variability: current status and future directions. Thromb Haemost 2009 ; 102: 7-14.
18. Yusuf S., Zhao F., Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 ; 345: 494-502. (Pubitemid 32758501)
19. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997 ; 30: 171-179.
20. Roffi M. and Topol EJ Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004 ; 25: 190-198. (Pubitemid 38235154)
21. Stuckey TD, Stone GW, Cox DA, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 2005 ; 95: 1-7. (Pubitemid 40051103)
22. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 2007 ; 116: 2762-2772. (Pubitemid 350291248)
23. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007 ; 116: e148 - e304.
24. Kushner FG, Hand M., Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009 ; 120: 2271-2306.
25. Patrono C., García Rodríguez LA, Landolfi R. and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 ; 353: 2373-2383. (Pubitemid 41713749)
26. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007 ; 30: 162-172. (Pubitemid 46052519)
27. Rydén L., Standl E., Bartnik M., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 ; 28: 88-136. (Pubitemid 46137814)
28. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 ; 296: 313-316. (Pubitemid 18042841)
29. Anon. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989 ; 321: 129-135.
30. Hansson L., Zanchetti A., Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 ; 351: 1755-1762. (Pubitemid 28269185)
31. Anon. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998 ; 351: 233-241.
32. Sacco M., Pellegrini F., Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003 ; 26: 3264-3272. (Pubitemid 37466885)
33. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005 ; 352: 1293-1304.
34. Anon. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992 ; 268: 1292-1300.
35. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008 ; 300: 2134-2141.
36. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008 ; 337: a1840.
37. Antithrombotic Trialists ' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373: 1849-1860.
38. De Berardis G., Sacco M., Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009 ; 339: b4531.
39. Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009 ; 32: 2300-2306.
40. Pignone M., Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010 ; 55: 2878-2886.
41. Colwell JA, American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004 ; 27 (Suppl 1). S72 - S73.
42. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983 ; 309: 396-403. (Pubitemid 13033964)
43. Théroux P., Ouimet H., McCans J., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988 ; 319: 1105-1111.
44. Anon. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990 ; 336: 827-830.
45. Anon. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988 ; 2: 349-360.
46. Roux S., Christeller S. and Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992 ; 19: 671-677.
47. Anon. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994 ; 308: 81-106.
48. Antithrombotic Trialists ' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 ; 324: 71-86.
49. Mehta SR and the Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Event/Optimal Antiplatelet Strategy for Interventions (CURRENT/OASIS7) trial. A 2x2 Factorial Randomized Trial of Optimal Clopidogrel and Aspirin Dosing in Patients With ACS Undergoing An Early Invasive Strategy With Intent For PCI. Late breaking clinical trial. Paper presented at: European Society of Cardiology Congress ; 2009 August 30-September 2; Barcelona, Spain.
50. Storey RF, Newby LJ and Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001 ; 12: 443-447. (Pubitemid 33097240)
51. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001 ; 86: 222-232. (Pubitemid 32663953)
52. Turner NA, Moake JL and McIntire LV Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001 ; 98: 3340-3345.
53. Bertrand ME, Rupprecht HJ, Urban P., Gershlick AH and Classics Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000 ; 102: 624-629. (Pubitemid 30640661)
54. Cadroy Y., Bossavy JP, Thalamas C., Sagnard L., Sakariassen K. and Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000 ; 101: 2823-2828. (Pubitemid 30396013)
55. Anon. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 ; 348: 1329-1339.
56. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W. and Topol EJ Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002 ; 90: 625-628. (Pubitemid 35264538)
57. Mehta SR, Yusuf S., Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001 ; 358: 527-533. (Pubitemid 32772726)
58. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 ; 288: 2411-2420. (Pubitemid 35340537)
59. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 ; 366: 1607-1621.
60. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 ; 352: 1179-1189. (Pubitemid 40397259)
61. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005 ; 294: 1224-1232. (Pubitemid 41352110)
62. Bhatt DL, Fox KA, Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 ; 354: 1706-1717.
63. Capranzano P., Ferreiro JL and Angiolillo DJ Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther 2009 ; 7: 361-369.
64. Wiviott SD, Trenk D., Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007 ; 116: 2923-2932. (Pubitemid 350291199)
65. Wiviott SD, Braunwald E., McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 ; 357: 2001-2015. (Pubitemid 350106708)
66. Wiviott SD, Braunwald E., McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008 ; 371: 1353-1363.
67. Wiviott SD, Braunwald E., Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008 ; 118: 1626-1636.
68. Angiolillo DJ, Badimon J., Saucedo JF, et al. Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3). Circulation 2009 ; 120: S 1027 [abstract 4946 ].
69. Roffi M., Chew DP, Mukherjee D., et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J 2002 ; 23: 1441-1448. (Pubitemid 36285576)
70. Roffi M., Chew DP, Mukherjee D., et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001 ; 104: 2767-2771. (Pubitemid 33126648)
71. Mehilli J., Kastrati A., Schühlen H., et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004 ; 110: 3627-3635. (Pubitemid 40003783)
72. Kastrati A., Mehilli J., Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006 ; 295: 1531-1538.
73. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001 ; 344: 1895-1903. (Pubitemid 32553358)
74. De Luca G., Navarese E. and Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009 ; 30: 2705-2713.
75. Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM and Bassand JP Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007 ; 28: 1193-1204. (Pubitemid 47343833)
76. Eikelboom JW, Mehta SR, Anand SS, Xie C., Fox KA and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006 ; 114: 774-782. (Pubitemid 44268228)
77. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 ; 355: 2203-2216. (Pubitemid 44791162)
78. Feit F., Manoukian SV, Ebrahimi R., et al. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2008 ; 51: 1645-1652. (Pubitemid 351635836)
79. Tavano D., Visconti G., D'Andrea D., et al. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol 2009 ; 104: 1222-1228.
80. Manoukian SV Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol 2009 ; 104 (Suppl): 9C - 15C.
81. Angiolillo DJ Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009 ; 103 (Suppl): 27A - 34A.
82. Michelson AD, Cattaneo M., Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005 ; 3: 1309-1311. (Pubitemid 41725257)
83. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG and Huisman MV Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007 ; 167: 1593-1599. (Pubitemid 47280339)
84. Krasopoulos G., Brister SJ, Beattie WS and Buchanan MR Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008 ; 336: 195-198. (Pubitemid 351212675)
85. Gurbel PA, Bliden KP, DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007 ; 115: 3156-3164. (Pubitemid 47012230)
86. Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006 ; 113: 2888-2896. (Pubitemid 44297229)
87. Watala C., Golanski J., Pluta J., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004 ; 113: 101-113. (Pubitemid 38534487)
88. Angiolillo DJ, Fernandez-Ortiz A., Bernardo E., et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006 ; 97: 38-43. (Pubitemid 41828120)
89. DiChiara J., Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007 ; 56: 3014-3019.
90. Davì G., Catalano I., Averna M., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990 ; 322: 1769-1774. (Pubitemid 20194655)
91. Guthikonda S., Lev EI, Patel R., et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007 ; 5: 490-496. (Pubitemid 46680680)
92. Serebruany V., Pokov I., Kuliczkowski W., Chesebro J. and Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008 ; 100: 76-82. (Pubitemid 351948748)
93. Singla A., Antonino MJ, Bliden KP, Tantry US and Gurbel PA The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2009 ; 158: 784.e1-6.
94. Angiolillo DJ, Bernardo E., Ramírez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006 ; 48: 298-304. (Pubitemid 44026661)
95. Angiolillo DJ, Bernardo E., Capodanno D., et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease on dual antiplatelet therapy. J Am Coll Cardiol 2010 ; 55: 1139-1146.
96. Dasgupta A., Steinhubl SR, Bhatt DL, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009 ; 103: 1359-1363.
97. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005 ; 293: 2126-2130. (Pubitemid 40617065)
98. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006 ; 26: 417-422. (Pubitemid 43732209)
99. Li Y., Woo V. and Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001 ; 280: H1480 - H1489.
100. Michno A., Bielarczyk H., Paweczyk T., Jankowska-Kulawy A., Klimaszewska J. and Szutowicz A. Alterations of adenine nucleotide metabolism and function of blood platelets in patients with diabetes. Diabetes 2007 ; 56: 462-467.
101. Guthikonda S., Alviar CL, Vaduganathan M., et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008 ; 52: 743-749.
102. Angiolillo DJ, Shoemaker SB, Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007 ; 115: 708-716. (Pubitemid 46294761)
103. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009 ; 157: 818-824.
104. Neri Serneri GG, Coccheri S., Marubini E., Violi F and Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004 ; 25: 1845-1852. (Pubitemid 39330236)
105. Anon. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994 ; 89: 588-595.
106. Gresele P., Migliacci R., Procacci A., De Monte P. and Bonizzoni E. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 2007 ; 97: 444-450. (Pubitemid 46437807)
107. Kariyazono H., Nakamura K., Arima J., et al. Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood. Blood Coagul Fibrinolysis 2004 ; 15: 157-167. (Pubitemid 38392368)
108. Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009 ; 27 (Suppl 3). 20-27.
109. Angiolillo DJ and Guzman LA Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 2008 ; 156: S23 - S28.
110. Capodanno D., Dharmashankar K. and Angiolillo DJ Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010 ; 8: 151-158.
111. Gurbel PA, Bliden KP, Butler K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/ OFFSET study. Circulation 2009 ; 120: 2577-2585.
112. Storey RF, Husted S., Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007 ; 50: 1852-1856. (Pubitemid 350017792)
113. Wallentin L., Becker RC, Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 ; 361: 1045-1057.
114. Ferreiro JL, Ueno M. and Angiolillo DJ Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009 ; 7: 1195-1201.
115. Storey RF, Wilcox RG and Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002 ; 13: 407-413. (Pubitemid 35346941)
116. Harrington RA, Stone GW, McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009 ; 361: 2318-2329.
117. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009 ; 361: 2330-2341.
118. Berger JS, Roe MT, Gibson CM, et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009 ; 158: 998-1004.
119. Ueno M., Rao SV and Angiolillo DJ Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol 2010 ; 6: 445-453.
120. Leonardi S., Rao SV, Harrington RA, et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010 ; 160: 65-72.
121. Angiolillo DJ, Capranzano P., Goto S., et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008 ; 29: 2202-2211.
122. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005 ; 112: 2826-2832. (Pubitemid 41641677)
123. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005 ; 46: 1833-1837.
124. Han Y., Li Y., Wang S., et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009 ; 157: 733-739.
125. Biondi-Zoccai GG, Lotrionte M., Anselmino M., et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008 ; 155: 1081-1089.
126. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008 ; 51: 1181-1187.
127. Ueno M., Ferreiro JL and Angiolillo DJ Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Rev Cardiovasc Ther 2010 ; 8: 1191-1200.
128. Angiolillo DJ, Capodanno D. and Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010 ; 31: 17-28.
129. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009 ; 373: 919-928.
130. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009 ; 158: 335-341.e3.
131. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J 2009 ; 158: 327-334.e4.
132. Wittkowsky AK New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 2010 ; 29: 182-191.